Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 38 out of 100. Vascular contributions

Topic: Brain proteins, microglia and lab models

Abstract INTRODUCTION Cerebral small vessel disease (CSVD) is the most prevalent pathology underlying vascular dementia. Increased neuroinflammation and blood‐brain barrier (BBB) permeability have been implicated in CSVD pathogenesis. We determined whether microglial reactivity and BBB permeability at baseline predicted whole‐brain and hippocampal atrophy over one year, and cognitive impairment over four years. METHODS Seventy‐seven patients with CSVD were recruited to this prospective study. Baseline microglial reactivity and BBB permeability were determined using 11 C‐PK11195 positron emission tomography and dynamic contrast enhanced (DCE) MRI respectively. RESULTS Greater 11 C‐PK11195 binding at baseline was associated with hippocampal atrophy over one year ( p = 0.001), but not with global brain atrophy. Cox regression analyses showed no significant associations between 11 C‐PK11195 and cognitive impairment. There were no associations between BBB permeability with whole‐brain and hippocampal atrophy, or with cognitive impairment. DISCUSSION Our data suggests that microglial reactivity may play a role in hippocampal atrophy; potentially contributing to the increasingly recognized interaction between vascular and neurodegenerative pathology.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Zainurin, A., Brown, R. B., Tozer, D. J., & Markus, H. S. (2026). Microglial reactivity predicts hippocampal, but not global, atrophy in cerebral small vessel disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz.71336

Vancouver

Zainurin A, Brown RB, Tozer DJ, Markus HS. Microglial reactivity predicts hippocampal, but not global, atrophy in cerebral small vessel disease. Alzheimer s & Dementia. 2026. doi:10.1002/alz.71336. PMID: 41927515.

BibTeX

@article{zainurin2026-41927515,
  author  = {Zainurin, Adriana and Brown, Robin B. and Tozer, Daniel J. and Markus, Hugh Stephen},
  title   = {{Microglial reactivity predicts hippocampal, but not global, atrophy in cerebral small vessel disease}},
  journal = {Alzheimer s \& Dementia},
  year    = {2026},
  doi     = {10.1002/alz.71336},
  pmid    = {41927515},
  url     = {https://doi.org/10.1002/alz.71336}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In 77 patients with cerebral small vessel disease, greater baseline microglial reactivity was associated with hippocampal atrophy over one year but not with global brain atrophy, and there were no significant associations with cognitive impairment. Blood-brain barrier permeability was not associated with atrophy or cognitive impairment, and the authors suggest microglial reactivity may play a role in hippocampal atrophy.

Study details

How this study scored 38/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multi-centre collaboration 0 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 38 of 100.38 of 100 points earned62 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 2 / 6 Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Hugh Stephen Markus: h-index 137 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Cambridge: institution h-index 1,973 (OpenAlex)
Multi-centre collaboration 0 / 3 OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41927515)
Free to read 2 / 2 Free to read
Total 38 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Vascular contributions

Also tagged “vessel”

900 studies in the library carry the topic tag “vessel”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 900 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Vascular contributions

See all studies in Vascular contributions →